In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species

Diagnostic Microbiology and Infectious Disease

Volumn 28, Issue 4, 1997, Pages 179-182

  Karlowsky, James A ^a,b   Zhanel, George G ^a   Balko, Tamara V ^a   Zelenitsky, Sheryl A ^a   Kabani, Amin M ^a   Hoban, Daryl J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; FLUCONAZOLE; KETOCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BLASTOMYCES; BLASTOMYCES DERMATITIDIS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; HUMAN; IN VITRO STUDY; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIFUNGAL AGENTS; BLASTOMYCES; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG RESISTANCE, MICROBIAL; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0030807353     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00061-8     Document Type: Article

References (10)

1. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Toison J, Henderson T, Marone WJ (1991) Secular trends in nosocomial primary bloodstream infections in the United States 1980-1989. Am J Med 91(suppl 3B):86S-89S.
2. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE (1995) In vitro antifungal and fungicidal spectra of a new pradimicin derivative. Antimicrob Agents Chemother 39:295-300.
3. Gonzalez CE, Shetty D, Giri N, Love W, Kligys K, Lyman C, Bacher J, Walsh TJ (1996a) Efficacy of pradimicin against disseminated candidiasis (abstr F181). In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans Washington, DC: American Society for Microbiology.
4. Gonzalez CE, Shetty D, Giri N, Love W, Kligys K, Sein T, Lyman C, Bacher J, Walsh TJ (1996b) Efficacy of pradimicin against invasive pulmonary aspergillosis (abstr F182). In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington, DC: American Society for Microbiology.
5. National Committee for Clinical Laboratory Standards (1995) Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standard M27-T. Villanova, PA: NCCLS.
6. Pfaller M, Wenzel R (1992) Impact of changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 11:287-291.
7. Ueki T, Numata K, Sawada Y, Nishio M, Ohkuma H, Toda S, Kamachi H, Fukagawa Y, Oki T (1993) Studies on the mode of antifungal action of pradimicin antibiotics, D-mannopyranoside-binding site and calcium-binding site. J Antibiot 46:455-464.
8. Vanden Bossche H, Warnock DW, Dupont B, Kerridge D, Sen Gupta S, Improvisi L, Marichal P, Odds FC, Provost F, Ronin O (1994) Mechanisms and clinical impact of antifungal resistance. J Med Vet Mycol 32(suppl 1):189-202.
9. Wardle HM, Law D, Denning DW (1996) In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida species. Antimicrob Agents Chemother 40:2229-2231.
10. Yang H, Drain RL, Clark JM (1994) Evaluation of the pradimicin analogue BMS-181184 against Pneumocystis carinii in an experimentally inoculated mice model (abstr F173). In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando. Washington, DC: American Society for Microbiology.